Subarachnoid Intracranial Hemorrhage — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for subarachnoid intracranial hemorrhage. 6 active patents protecting 1 drugs from 0+ originators. First major cliff: 2038. Daily refresh.

1
Approved drugs
6
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Subarachnoid Intracranial Hemorrhage

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating subarachnoid intracranial hemorrhage. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Nimotop
NIMODIPINE
 — 6 65 — 2038-04-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12186308 Nimotop method of use 75 2038-04-16
11207306 Nimotop method of use 70 2038-04-16
11413277 Nimotop method of use 70 2038-04-16
10342787 Nimotop method of use 62 2038-04-16
10576070 Nimotop method of use 62 2038-04-16
11806338 Nimotop formulation 50 2038-04-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11806338 Nimotop formulation 50 2038-04-16
10342787 Nimotop method of use 62 2038-04-16
10576070 Nimotop method of use 62 2038-04-16
11207306 Nimotop method of use 70 2038-04-16
11413277 Nimotop method of use 70 2038-04-16
12186308 Nimotop method of use 75 2038-04-16

Related